References
- Świtaj P, Anczewska M, Chrostek A, et al. Disability and schizophrenia: a systematic review of experienced psychosocial difficulties. BMC Psychiatry 2012;12:193
- Bellack AS, Green MF, Cook JA, et al. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull 2007;33:805-22
- Knapp M. Costs of schizophrenia. Psychiatry 2005;4:33-5
- Maguire GA. Comprehensive understanding of schizophrenia and its treatment. Am J Health Syst Pharm 2002;59(Suppl 5):S4-11
- Knapp M. Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand Suppl 2000;407:15-18
- NICE Schizophrenia Guidelines CG178, February 2014. Available at: http://www.nice.org.uk/nicemedia/live/14382/66534/66534.pdf [Last accessed 18 February 2014]
- Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
- Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87
- Paliperidone ER SmPC. Janssen. August 2013. Available at: http://www.medicines.org.uk/EMC/medicine/19828/SPC/INVEGA+1.5+mg%2c+3+mg%2c+6+mg%2c+9+mg%2c+12+mg+prolonged-release+tablets/ [Last accessed 17 February 2014]
- Lautenschlager M, Heinz A. Paliperidone-ER: first atypical antipsychotic with oral extended release formulation. Expert Rev Neurother 2008;8:193-200
- Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-30
- Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
- Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-70
- Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007;27:6-14
- Wang SM, Han C, Lee SJ, et al. Paliperidone: a review of clinical trial data and clinical implications. Clin Drug Investig 2012;32:497-512
- Schmauss M, Jukić V, Siracusano A, et al. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study. Curr Med Res Opin 2012;28:1395-404
- Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case–control study of risks versus benefits. Am J Psychiatry. 2004;161:700-6
- Amisulpride SmPC. May 2013. Sanofi-Aventis. Available at: http://www.medicines.org.uk/EMC/medicine/26091/SPC/Amisulpride+100mg+Tablets/ [Last accessed 17 February 2014]
- Aripiprazole SmPC. November 2013. Otsuka. Available at: http://www.medicines.org.uk/EMC/medicine/18494/SPC/Abilify+Tablets%2c+Orodispersible+Tablets%2c+Oral+Solution+(Otsuka+%26+Bristol-Myers+Squibb)/[Last accessed 17 February 2014]
- Olanzapine SmPC. October 2012. Accord. Available at: http://www.medicines.org.uk/EMC/medicine/25892/SPC/Olanzapine+20+mg+Film-coated+Tablets/ [Last accessed 17 February 2014]
- Quetiapine SmPC. February 2013. Actavis. Available at: http://www.medicines.org.uk/emc/medicine/26237/SPC/Quetiapine+25mg+film-coated+tablets/ [Last accessed 17 February 2014]
- Risperidone SmPC. October 2013. Janssen-Cilag. Available at: http://www.medicines.org.uk/EMC/medicine/24905/SPC/Risperidone+4+mg+Tablets/ [Last accessed 17 February 2014]
- Ziprasidone SmPC. July 2013. Pfizer. Available at: http://www.medicines.ie/medicine/6166/SPC/GEODON+Capsules+20mg,+40mg,+60mg,+80mg/[Last accessed 17 February 2014]
- Wang Y, Li WS, Gu DK, et al. [Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study]. Zhonghua Yi Xue Za Zhi 2010;90:2030-5
- Schreiner A, Niehaus D, Shuriquie NA, et al. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol 2012;32:449-57
- De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77
- Jones S, Howard L, Thornicroft G. ‘Diagnostic overshadowing’: worse physical health care for people with mental illness. Acta Psychiatr Scand 2008;118:169-71
- Joukamaa M, Heliövaara M, Knekt P, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:122-7
- Suokas JT, Suvisaari JM, Haukka J, et al. Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol 2013;48:631-8
- Roh D, Chang JG, Kim CH, et al. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust N Z J Psychiatry 2014;48:52-60
- Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
- Canuso CM, Grinspan A, Kalali A, et al. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol 2010;25:155-64
- Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20:389-409